NEW YORK, Feb. 16, 2022 /PRNewswire/ -- The Gross Law
Firm issues the following notice on behalf of shareholders of
Reata Pharmaceuticals, Inc..
Shareholders who purchased shares of RETA during the class
period listed are encouraged to contact the firm regarding possible
lead plaintiff appointment. Appointment as lead plaintiff is not
required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/reata-pharmaceuticals-inc-loss-submission-form-2/?id=23701&from=4
CLASS PERIOD: This lawsuit is on behalf of persons and
entities that purchased or otherwise acquired Reata securities,
and/or sold Reata put options, between November 9, 2020 and December 8, 2021, inclusive.
ALLEGATIONS: The complaint alleges that during the class
period, Defendants issued materially false and/or misleading
statements and/or failed to disclose that: (1) the Food and Drug
Administration had raised concerns regarding the validity of the
clinical study designed to measure the efficacy and safety of
bardoxolone for the treatment of chronic kidney disease caused by
Alport syndrome; (2) as a result, there was a material risk that
Reata's New Drug Application would not be approved; and (3) as a
result of the foregoing, defendants' positive statements about the
Company's business, operations, and prospects were materially
misleading and/or lacked a reasonable basis.
DEADLINE: February 18,
2022 Shareholders should not delay in registering
for this class action. Register your information here:
https://securitiesclasslaw.com/securities/reata-pharmaceuticals-inc-loss-submission-form-2/?id=23701&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of RETA during the timeframe
listed above, you will be enrolled in a portfolio monitoring
software to provide you with status updates throughout the
lifecycle of the case. The deadline to seek to be a lead plaintiff
is February 18, 2022. There is no
cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law Firm is
committed to ensuring that companies adhere to responsible business
practices and engage in good corporate citizenship. The firm seeks
recovery on behalf of investors who incurred losses when false
and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original
content:https://www.prnewswire.com/news-releases/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-reata-pharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-february-18-2022--nasdaq-reta-301482928.html
SOURCE The Gross Law Firm